We are live on ! Find out more
BBLG

Bone Biologics
BBLG

3 hedge funds and large institutions have $67K invested in Bone Biologics in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 3 → 3 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

58% less capital invested

Capital invested by funds: $160K → $67K (-$93K)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$13.2K
2
TRCT
Tower Research Capital (TRC)
New York
+$10.6K

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$37K
2
Citadel Advisors
Citadel Advisors
Florida
-$30K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$47K – – –
UBS Group
2
UBS Group
Switzerland
$11K +$13.2K +5 New
TRCT
3
Tower Research Capital (TRC)
New York
$9K +$10.6K +4 New
Jane Street
4
Jane Street
New York
– -$37K -9 Closed
Citadel Advisors
5
Citadel Advisors
Florida
– -$30K -7 Closed

BBLG Hedge Fund Activity: Q2 2022 in Review

3 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q2 2022, worth a combined $67K — down 58% from $160K a quarter earlier.

Fund positioning in BBLG was balanced in Q2 2022: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $13.2K. The largest seller was Jane Street, exiting entirely with an estimated $37K sold.

  • 3 institutional investors held Bone Biologics (BBLG) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $67K of Bone Biologics stock for Q2 2022, down 58% quarter-over-quarter.
  • 2 funds opened new Bone Biologics positions in Q2 2022 and 2 closed out, a net change of 0 holders.
  • The largest Bone Biologics buyer in Q2 2022 was UBS Group, an estimated $13.2K added.
  • The largest Bone Biologics seller in Q2 2022 was Jane Street, an estimated $37K sold.

Based on aggregated 13F filings for Q2 2022.